European cannabis company, EMMAC has announced the expansion of its research collaboration with Imperial College London (ICL) which focuses on evaluating the cannabinoid entourage effect for pain treatment using in vitro models and a range of medicinal cannabis combination products.
The collaboration expansion between EMMAC and ICL builds upon their existing comprehensive long-term research program which is designed to educate and mold the future of cannabis-based therapies.
The program will focus on researching the mechanisms of action of medicinal cannabis products and how they relate to clinical applications including pain and cancer.
“This is a very exciting area of pain research, which aims to characterise the entourage effect and related mechanisms of cannabis-based medicine combinations at a molecular level,” said Imperial College London Professor Praveen Anand. “Our results may support the rational design of future clinical trials to enhance pain relief and minimise adverse effects. We look forward to working with EMMAC in developing these experimental platforms and pipelines, to advance the treatment of patients with neuropathic pain.”
Under the collaboration agreement, EMMAC and ICL will fund a post-doctoral research position for an extendable one-year period to study the efficacy of EMMAC products in the treatment of neuropathic pain and aid in their development toward clinical trials.
Chief Operating Officer at EMMAC, Tom Rooke says that the partnership between EMMAC and ICL is an important factor in furthering the industry’s comprehension of the medicinal benefits of cannabis.
EMMAC expects to collaborate with ICL on a variety of additional cannabinoid research programs in the future.
